Targeted delivery of anti-osteoporosis therapy: Bisphosphonate-modified nanosystems and composites

Shi, Shaoyan; Duan, Honghao; Ou, Xuehai

doi:10.1016/j.biopha.2024.116699

Biomedicine & Pharmacotherapy

2024

DOI: 10.1016/j.biopha.2024.116699

|View full text |Cite

Targeted delivery of anti-osteoporosis therapy: Bisphosphonate-modified nanosystems and composites

Shaoyan Shi,

Honghao Duan,

Xuehai Ou

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

2025

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 72 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Ubiquitination and deubiquitination: Implications for the pathogenesis and treatment of osteoarthritis

Su,

Tian,

Jiao

et al. 2024

Journal of Orthopaedic Translation

View full text Add to dashboard Cite

Ubiquitination and deubiquitination: Implications for the pathogenesis and treatment of osteoarthritis

Su,

Tian,

Jiao

et al. 2024

Journal of Orthopaedic Translation

View full text Add to dashboard Cite

Targeted Drug Delivery for Precision Mitochondrial Therapy in Osteoporosis: Therapeutic Strategies and Advances

He,

Zeng,

et al. 2025

CDTH

View full text Add to dashboard Cite

Osteoporosis (OP) remains a significant global health challenge, marked by high prevalence and considerable economic burden, yet effective therapeutic options remain limited. Central to the pathogenesis of OP is mitochondrial dysfunction, which adversely impacts bone formation and resorption. This review provides an in-depth analysis of the complex relationship between mitochondrial function and OP, elucidating critical molecular mechanisms and identifying promising therapeutic agents. Among these, zoledronic acid and resveratrol stand out, demonstrating significant efficacy in enhancing mitochondrial functions and enhancing bone density in both preclinical models and clinical trials. Moreover, innovative drug delivery systems, such as mitochondrial-targeted nanodelivery systems and localized delivery methods, have been developed to ensure precise targeting and reduce systemic side effects, thereby enhancing bioavailability and therapeutic outcomes. By delving into these advancements, this review seeks to facilitate the translation of mitochondrial-targeted therapies from preclinical research to clinical application, ultimately advancing OP management and improving patient outcomes.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Targeted delivery of anti-osteoporosis therapy: Bisphosphonate-modified nanosystems and composites

Cited by 2 publications

References 72 publications

Ubiquitination and deubiquitination: Implications for the pathogenesis and treatment of osteoarthritis

Ubiquitination and deubiquitination: Implications for the pathogenesis and treatment of osteoarthritis

Targeted Drug Delivery for Precision Mitochondrial Therapy in Osteoporosis: Therapeutic Strategies and Advances

Contact Info

Product

Resources

About